| Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Oct 25 | ETNB 89bio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.6 | 56,400 | 541.44 k | 0 |
| 30 Oct 25 | ETNB 89bio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.98 | 45,150 | 450.60 k | 0 |
| 30 Oct 25 | ETNB 89bio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 14.7 | 27,400 | 402.78 k | 0 |
| 30 Oct 25 | ETNB 89bio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.64 | 25,000 | 66.00 k | 0 |
| 30 Oct 25 | ETNB 89bio | Stock Option Common Stock | Sale back to company | Dispose D | Yes | No | 24.16 | 12,500 | 302.00 k | 0 |
| 30 Oct 25 | ETNB 89bio | Stock Option Common Stock | Sale back to company | Dispose D | Yes | No | 24.29 | 7,000 | 170.03 k | 0 |
| 30 Oct 25 | ETNB 89bio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 21.4 | 7,000 | 149.80 k | 0 |
| 13 Jun 25 | ACRV Acrivon Therapeutics, Inc. Common Stock | Stock Option Common Stock | Grant | Acquire A | No | No | 1.2 | 20,275 | 24.33 k | 20,275 |
| 13 Feb 25 | MLYS Mineralys Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 10.2 | 32,900 | 335.58 k | 32,900 |
| 3 Feb 25 | ETNB 89bio | Stock Option Common Stock | Grant | Acquire A | No | No | 9.6 | 56,400 | 541.44 k | 56,400 |
